London-based wealth manager Henderson Rowe has partnered with Elivisa Consulting (Elivisa), a global immigration services company, to provide dedicated investment services to qualified investors participating in the UK Tier 1 Investor Visa programme.
The tie-up aims to capitalize on growth opportunities in Tier 1 Investor Visa applications from China to the UK, which doubled year-on-year in the first half of this year.
As a result of the partnership, Henderson Rowe has become the preferred provider of UK investor visa services for Elivisa’s clients. The UK Tier 1 Investor Visa is Britain’s most exclusive residency by investment program.
Elivisa is an affiliate of China-based wealth and asset management service provider Noah Holdings, which focuses on high-net-worth individuals in the Chinese market.
The inward investment scheme grants non-EU nationals the right to reside in the UK by way of investment. Based on quantum of investment, the programme offers three different paths, starting with a minimum investment of 2 million pounds (US$2.49 million), to achieve “indefinite leave to remain” status after five years and, ultimately, a UK passport after an additional year.
In the first half of this year, total Tier 1 Visa applications grew by 36 percent year-on-year, with applications from China accounting for more than 40 percent overall, according to data from Elivisa.
Despite the shadow of uncertainty cast by Brexit, according to Joanne Wang, head of Elivisa the UK has long been a top destination for global investors. As well as access to high standards of living and schooling, the UK is seen as offering a vibrant financial market with a favourable tax regime.
“Our success is built upon providing a bespoke and personalised service for all clients. We are delighted to expand our network with the Elivisa partnership and look forward to working with their Tier 1 Visa qualified clients to offer institutional-quality solutions that blend advanced quantitative core portfolios with high-conviction fundamental stock selections,” says Artur Baluszynski, director and head of research at Henderson Rowe.